Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Key facts
- Where
- Aachen, Berlin, Frankfurt, Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Mainz, Munich, Münster, Regensburg, and Tübingen, GermanySee the 14 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04613921, who can take part
Where in Germany
- University Hospital AachenAachen, GermanyContact: Anna BoschNo longer taking part
- Charité University HospitalBerlin, GermanyContact: Cornelius EngelmannTaking people
- Goethe University ClinicFrankfurt, GermanyContact: Alexander QueckNot yet recruiting
- University Medical Center Hamburg-EppendorfHamburg, GermanyContact: Lutz FischerTaking people
- Hannover Medical SchoolHanover, GermanyContact: Richard TaubertNot yet recruiting
- University Hospital HeidelbergHeidelberg, GermanyContact: Arianeb MehrabiNot yet recruiting
- Jena University HospitalJena, GermanyContact: Anna BoschNo longer taking part
- Universitätsklinikum Schleswig-Holstein (UKSH)Kiel, GermanyContact: Thomas Becker, ProfNot yet recruiting
- Leipzig University HospitalLeipzig, GermanyContact: Thomas BergNot yet recruiting
- University Hospital MainzMainz, GermanyContact: Anna BoschNo longer taking part
- LMU GroßhadernMunich, GermanyContact: Anna BoschNo longer taking part
- UKM MuensterMünster, GermanyContact: Jonel TrebickaTaking people
- University Hospital RegensburgRegensburg, GermanyContact: Martina Müller-Schilling, MDNot yet recruiting
- University Hospital TübingenTübingen, GermanyContact: Silvio NadalinTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Foundation for Study of Chronic Liver Failure
- Trial code
- NCT04613921
- Record updated
- 20 October 2025
- Original description
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.Read full original descriptionShow less
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.
Inclusion: 1. Male or female subject ≥18 years of age; Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology); Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:; Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list; Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD>20) at the time of listing; Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation; Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria.
Exclusion: -.